



## INFORMATION DISCLOSURE STATEMENT

Applicant : David M. Weiner, et al.  
App. No : 10/759,561  
Filed : January 15, 2004  
For : SELECTIVE SEROTONIN 2A/2C  
RECEPTOR INVERSE AGONISTS AS  
THERAPEUTICS FOR  
NEURODEGENERATIVE DISEASES  
Examiner : Leonard M. Williams  
Art Unit : 1617

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

8-3-07

(Date)

Ryan E. Melnick, Reg. No. 58,621

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 13 references to be considered by the Examiner. Also enclosed are nine foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON &amp; BEAR, LLP

Dated: 8-3-07

By:

Ryan E. Melnick  
Registration No. 58,621  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(Multiple sheets used when necessary)*

SHEET 1 OF 1

Application No.	10/759,561
Filing Date	January 15, 2004
First Named Inventor	David M. Weiner, et al.
Art Unit	1617
Examiner	Williams, Leonard M.
Attorney Docket No.	ACADIA.030A

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,150,393	11-21-2000	Behan, et al.	
	2	6,479,480	11-12-2002	Moyes, et al.	
	3	6,486,153	11-26-2002	Castro Pineiro, et al.	
	4	2002/0156068	10-24-2002	Behan et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	5	WO 2002/076464 A1	10-03-2002	Arena Pharmaceuticals, Inc.		
	6	WO 2003/062206 A2	07-31-2003	Arena Pharmaceuticals, Inc.		
	7	WO 2004/039322 A2	05-13-2004	Micro, Inc.		
	8	WO 2004/064738 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
	9	WO 2004/064753 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
	10	WO 2005/053796 A1	06-16-2005	B&B Beheer NV		
	11	WO 2005/063254 A2	07-14-2005	Acadia Pharmaceuticals Inc.		
	12	WO 2006/104826	10-05-2006	Merck & Co., Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	13	International Search Report and Written Opinion from PCT/US2005/017808 mailed September 29, 2005.	

4096691:sad  
080307

Examiner Signature

Date Considered

**\*Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.